173 related articles for article (PubMed ID: 2373131)
1. Subjective symptoms and pharmacokinetics/dynamics of metoprolol CR in elderly subjects--a comparison with atenolol.
Dimenäs ES; Dahlöf CG; Heibel B; Moore RG; Olofsson BK; Westergren GE; Lücker PW
Eur J Clin Pharmacol; 1990; 38(6):571-8. PubMed ID: 2373131
[TBL] [Abstract][Full Text] [Related]
2. Comparison of CNS-related subjective symptoms in hypertensive patients treated with either a new controlled release (CR/ZOK) formulation of metoprolol or atenolol.
Dimenäs E; Ostergren J; Lindvall K; Dahlöf C; Westergren G; de Faire U
J Clin Pharmacol; 1990 Feb; 30(S2):S82-90. PubMed ID: 2179286
[TBL] [Abstract][Full Text] [Related]
3. Beta-adrenoceptor blockade and CNS-related subjective symptoms: a randomized, double-blind, placebo-controlled comparison of metoprolol CR/ZOK, atenolol and propranolol LA in healthy subjects.
Dimenäs E; Kerr D; Macdonald I
J Clin Pharmacol; 1990 Feb; 30(S2):S103-7. PubMed ID: 1968912
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of controlled-release metoprolol: a comparison with atenolol.
Blomqvist I; Westergren G; Sandberg A; Jonsson UE; Lundborg P
Eur J Clin Pharmacol; 1988; 33 Suppl():S19-24. PubMed ID: 3371390
[TBL] [Abstract][Full Text] [Related]
5. Effects of 100 mg of controlled-release metoprolol and 100 mg of atenolol on blood pressure, central nervous system-related symptoms, and general well being.
Walle PO; Westergren G; Dimenäs E; Olofsson B; Albrektsen T
J Clin Pharmacol; 1994 Jul; 34(7):742-7. PubMed ID: 7929868
[TBL] [Abstract][Full Text] [Related]
6. CNS-related subjective symptoms during treatment with beta 1-adrenoceptor antagonists (atenolol, metoprolol): two double-blind placebo controlled studies.
Dimenäs E; Dahlöf C; Olofsson B; Wiklund I
Br J Clin Pharmacol; 1989 Nov; 28(5):527-34. PubMed ID: 2574052
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic properties of controlled release (CR/ZOK) metoprolol in healthy Oriental subjects: a comparison with conventional formulations of metoprolol and atenolol.
Darmansjah I; Wong E; Setiawati A; Moeloek D; Irawati D; Siagian M; Muchtar A
J Clin Pharmacol; 1990 Feb; 30(S2):S39-45. PubMed ID: 2312778
[TBL] [Abstract][Full Text] [Related]
8. Exercise metabolism in healthy volunteers taking atenolol, high and low doses of metoprolol CR/Z0K, and placebo.
Head A; Maxwell S; Kendall MJ; Eagles C
Br J Clin Pharmacol; 1994 Dec; 38(6):499-504. PubMed ID: 7888287
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses.
Lücker P; Moore G; Wieselgren I; Olofsson B; Bergstrand R
J Clin Pharmacol; 1990 Feb; 30(S2):S17-27. PubMed ID: 2312775
[TBL] [Abstract][Full Text] [Related]
10. The effects of combined treatment with beta 1-selective receptor antagonists and lipid-lowering drugs on fat metabolism and measures of fatigue during moderate intensity exercise: a placebo-controlled study in healthy subjects.
Eagles CJ; Kendall MJ
Br J Clin Pharmacol; 1997 Mar; 43(3):291-300. PubMed ID: 9088584
[TBL] [Abstract][Full Text] [Related]
11. Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease.
Plosker GL; Clissold SP
Drugs; 1992 Mar; 43(3):382-414. PubMed ID: 1374320
[TBL] [Abstract][Full Text] [Related]
12. A double-blind comparison of metoprolol CR/ZOK 50 mg and atenolol 50 mg once daily for uncomplicated hypertension.
Klein G; Berger J; Olsson G; Menzel T
J Clin Pharmacol; 1990 Feb; 30(S2):S72-7. PubMed ID: 2179284
[TBL] [Abstract][Full Text] [Related]
13. Controlled-release metoprolol compared with atenolol in asthmatic patients: interaction with terbutaline.
Löfdahl CG; Dahlöf C; Westergren G; Olofsson B; Svedmyr N
Eur J Clin Pharmacol; 1988; 33 Suppl():S25-32. PubMed ID: 2836204
[TBL] [Abstract][Full Text] [Related]
14. Metabolic effects of controlled-release metoprolol in hypertensive men with impaired or diabetic glucose tolerance: a comparison with atenolol.
Fagerberg B; Berglund A; Holme E; Wilhelmsen L; Elmfeldt D
J Intern Med; 1990 Jan; 227(1):37-43. PubMed ID: 2405089
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic comparison of a new controlled-release formulation of metoprolol with a traditional slow-release formulation.
Oosterhuis B; Jonkman JH; Kerkhof FA
Eur J Clin Pharmacol; 1988; 33 Suppl():S15-8. PubMed ID: 3371389
[TBL] [Abstract][Full Text] [Related]
16. Effects of a week's beta-adrenoceptor blockade with atenolol and metoprolol CR/ZOK on the response to exercise in healthy women aged 50 to 70 years.
Patrick J; Bassey J; Morrant J; Macdonald I
J Clin Pharmacol; 1990 Feb; 30(S2):S108-16. PubMed ID: 2312773
[TBL] [Abstract][Full Text] [Related]
17. A pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK with a conventional slow release preparation.
Oosterhuis B; Jonkman J; Zuiderwijk P; Sollie F
J Clin Pharmacol; 1990 Feb; 30(S2):S33-8. PubMed ID: 2312777
[TBL] [Abstract][Full Text] [Related]
18. Treatment with beta-blockers--the value of an even plasma concentration over 24 h.
Agewall S; Kendall M
J Clin Pharm Ther; 1997 Jun; 22(3):171-9. PubMed ID: 9447471
[TBL] [Abstract][Full Text] [Related]
19. A comparison of metoprolol OROS with antenolol in the treatment of effort angina pectoris: a randomized double-blind study.
Floris B; Paoletti G; Pelizza L; Bertulla A; Motolese M
Int J Clin Pharmacol Ther Toxicol; 1991 Apr; 29(4):139-43. PubMed ID: 1906434
[TBL] [Abstract][Full Text] [Related]
20. Is metoprolol CR/ZOK more selective than conventional metoprolol and atenolol?
Kendall M; Akhlaghi S; Hughes B; Lewis H
J Clin Pharmacol; 1990 Feb; 30(S2):S98-102. PubMed ID: 2155948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
